Iambic Therapeutics at a glance
- Headquarters
- San Diego, California, USA[1]
- [1] Headquarters: SEC EDGAR Form D (retrieved September 9, 2026)
Is this your company? Get featured or correct your listing →
Recent changes
- Oct 14, 2026Oct 14, 2026IPO $150M at ~$758M SEC EDGAR (424B4 final prospectus)
- Oct 14, 2026Oct 14, 2026First reported valuation: ~$758MRumored SEC EDGAR (424B4 final prospectus)
- Oct 8, 2026Oct 8, 2026Iambic Therapeutics Sets Terms For $150M Nasdaq IPO Pulse story
- Aug 14, 2026Aug 14, 2026Raised $66M SEC EDGAR Form D
Funding history
1 equity event · newest first · sources dated per row| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Aug 14, 2026 | Funding roundnot counted | $66M | — | — | SEC EDGAR Form D |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
Debt, IPO & other events
not counted in equity raised| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Oct 14, 2026 | ipo | $150M | ~$758M | SEC EDGAR (424B4 final prospectus) |
Investors
Latest Pulse
- Oct 23, 2026Pathos AI Hits $3B Valuation In $237M Round Led By BMSPathos AI raised $237 million in a Series E led by Bristol Myers Squibb at a $3 billion valuation, as Big Pharma deepens its direct bet on AI-designed cancer drugs.→
- Oct 21, 20262026's IPO Window Rewards Proof, Not PromisePublic investors aren't closing the IPO window in 2026 -- they're being unsparing toward growth stories without current profitability, pricing modest biotech and SPAC deals while mega-valuation infrastructure names keep stalling.→
- Oct 21, 2026Firmus's IPO Pullback Widens 2026's $257B Exit GapPulse's tracker counts $257.4B in private VC funding over 21 weeks against just $830M in disclosed IPO pricings the same week, and Firmus's renewed struggle to go public shows why the gap keeps widening.→
- Oct 19, 2026Why 2026's Funding Boom Hasn't Produced More IPO ExitsPulse's funding tracker counts $257.4 billion in private deals over 21 weeks, but this week's two largest disclosed IPO pricings totaled just $830 million -- a sign the biggest private companies are choosing to keep raising rather than go public.→
- Oct 19, 2026Biotech Is Carrying 2026's IPO Market While Megacap Tech WaitsBiotech IPOs are pricing and popping this month while the biggest tech listings investors actually want -- Anthropic and OpenAI -- remain stuck in pre-IPO limbo.→
- Oct 18, 2026This Week's IPOs Show Investors Being Picky, Not BullishStrive and City Therapeutics priced IPOs worth a combined $830 million this week while Firmus Grid withdrew its $30 billion data-center listing, splitting the IPO market into clear winners and one high-profile retreat.→
- Oct 16, 20264 IPOs Priced In 24 Hours, One Already Popped 18%Four IPOs priced within a single 24-hour stretch this week, from Strive's $630M preferred offering to Iambic Therapeutics' 18% debut pop, while Amaero priced at $4.25/share for roughly $20 million -- about 40% below its original $7.06 target price, with the deal cut from more than $50 million to $20 million.→
- Oct 16, 2026City Therapeutics Prices Upsized $200M IPO At $18City Therapeutics priced its upsized IPO at $18 a share for about $200 million in gross proceeds, above the terms Pulse covered in early October, with Nasdaq trading under ticker CTY starting October 16.→
- Oct 15, 2026OrbiMed Raises $3B Across Two New Healthcare FundsOrbiMed closed $3 billion across two new vehicles, OrbiMed Private Investments X for US and European life sciences venture capital and OrbiMed Asia Partners VI for Asian healthcare growth equity, bringing the firm's total assets past $21 billion.→
- Oct 15, 2026Iambic Prices $150M IPO At $16, Pops On Nasdaq DebutIambic Therapeutics priced its IPO at $16 a share, raising $150 million and debuting on Nasdaq under IAM, with shares closing up 18.19% at $18.91 on Thursday after Pulse covered its upsized terms last week.→
Coverage Timeline
newest first- Oct 16, 2026IPO4 IPOs Priced In 24 Hours, One Already Popped 18%→
- Oct 15, 2026IPOIambic Prices $150M IPO At $16, Pops On Nasdaq Debut$150M IPO ($16/Share)→
- Oct 11, 2026IPOIambic's Upsized IPO Terms Hint At Real Demand→
- Oct 8, 2026IPOIambic Therapeutics Sets Terms For $150M Nasdaq IPO$150M IPO→
- Sep 21, 2026IPONvidia, Qatar-Backed AI Drug Startup Iambic Files For IPO~$5.49B market cap→
All Coverage
IPO
4 IPOs Priced In 24 Hours, One Already Popped 18%
Four IPOs priced within a single 24-hour stretch this week, from Strive's $630M preferred offering to Iambic Therapeutics' 18% debut pop, while Amaero priced at $4.25/share for roughly $20 million -- about 40% below its original $7.06 target price, with the deal cut from more than $50 million to $20 million.
BY THE NUMBERS
Iambic Prices $150M IPO At $16, Pops On Nasdaq Debut
IPO$150M IPO ($16/Share)
Iambic Prices $150M IPO At $16, Pops On Nasdaq Debut
Iambic Therapeutics priced its IPO at $16 a share, raising $150 million and debuting on Nasdaq under IAM, with shares closing up 18.19% at $18.91 on Thursday after Pulse covered its upsized terms last week.
FOLLOW-UP
Iambic's Upsized IPO Terms Hint At Real Demand
IPO
Iambic's Upsized IPO Terms Hint At Real Demand
Iambic Therapeutics raised its own IPO target from roughly $100 million to $150 million this week, a rare upward revision at a moment when a much larger data-center listing was being withdrawn entirely.
DEEP DIVE
Iambic Therapeutics Sets Terms For $150M Nasdaq IPO
IPO$150M IPO
Iambic Therapeutics Sets Terms For $150M Nasdaq IPO
Iambic Therapeutics set terms for a $150 million Nasdaq IPO at $15-$17 a share, up sharply from the roughly $100 million it originally sought when it filed in September.
FOLLOW-UP
Nvidia, Qatar-Backed AI Drug Startup Iambic Files For IPO
IPO~$5.49B market cap
Nvidia, Qatar-Backed AI Drug Startup Iambic Files For IPO
Iambic Therapeutics, an AI-driven drug discovery company backed by Nvidia and Qatar's sovereign wealth fund, filed for a US IPO at a roughly $5.49 billion market cap amid a busy fall pipeline of AI-adjacent biotechs.
DEEP DIVE
Value Add Research
- AI & Technology · Oct 9, 2026Iambic Therapeutics IPO: Priced at $16, Now Trading as IAM
- VC & Investing · Oct 20, 2026Lycia Therapeutics IPO 2026: $938M Valuation, LYCA Ticker
- Fundraising · Oct 14, 2026TRexBio IPO 2026: $116.7M Raise, Lilly Eyes Bigger Stake
- VC & Investing · Oct 13, 2026City Therapeutics IPO: $230M at $18 a Share (CTY)
- Market & Trends · Oct 13, 2026Gravitics IPO: Still Unpriced, $50M Cut (Nov 1, 2026)
- VC & Investing · Sep 30, 2026ADARx IPO: $1.81B Valuation, $446M Raised (ADRX)
- VC & Investing · Jul 15, 2026$400M at $3.8B — Chai Discovery AI Drug Design
- Market & Trends · Jul 10, 2026$5B+ Raised — AI Drug Discovery Startups (2026)
Related Companies
Shared investors
Iambic Therapeutics FAQ
Where is Iambic Therapeutics headquartered?
Iambic Therapeutics is headquartered in San Diego, California, USA, according to SEC EDGAR Form D.
Sources & methodologyshow
Where these figures come from
- SEC EDGAR (424B4 final prospectus)primary source1 fact
- SEC EDGAR Form Dprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.